Company: SWKH
Filing Date: 2025-08-14
Form Type: 10-Q
Source: 0001628280-25-040420
Chunk: 46

Company: SWK Holdings Corp
Filing Date: 2025-08-14
Form: 10-Q
Item: Part I, Item 1
Chunk 46
---
1)Significant  Other  Observable  Inputs  (Level 2)Significant  Unobservable  Inputs  (Level 3)June 30, 2025$12,312 $— $— $12,312 December 31, 2024$14,830 $— $— $14,830     There were no liabilities measured at fair value on a nonrecurring basis as of June 30, 2025 and December 31, 2024.The following information is provided to help readers gain an understanding of the relationship between amounts reported in the accompanying unaudited condensed consolidated financial statements and the related market or fair value. The disclosures include financial instruments and derivative financial instruments measured at fair value on a recurring and non-recurring basis.The following table presents the fair value of financial assets as of June 30, 2025 (in thousands):Carrying ValueFair ValueLevel 1Level 2Level 3Financial AssetsFinance receivables, net$237,604 $237,604 $— $— $237,604 Marketable investments603 603 597 — 6 Warrant assets4,612 4,612 — — 4,612 

22

The following table presents the fair value of financial assets and liabilities as of December 31, 2024 (in thousands):Carrying ValueFair ValueLevel 1Level 2Level 3Financial AssetsFinance receivables, net$277,760 $277,760 $— $— $277,760 Marketable investments580 580 559 — 21 Warrant assets4,366 4,366 — — 4,366 Foreign currency forward contract2,475 2,475 — — 2,475 

Note 9. Revenue Recognition

The Company's Pharmaceutical Development segment recognizes revenues received from contracts with its customers by revenue source, as we believe it best depicts the nature, amount, timing and uncertainty of our revenue and cash flow. The Company's Finance Receivables segment does not have any revenues received from contracts with customers.The following table provides the contract revenue recognized by revenue source (in thousands):Three Months EndedJune 30,Six Months EndedJune 30,2025202420252024Pharmaceutical Development SegmentLicense Agreement$— $49 $— $49 Pharmaceutical Development 1,190